GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a statement in response to the World Health Organization’s ...

Preclinical Studies Demonstrate Durable Protection Against SARS-CoV-2 Variants, Including Omicron XBB.1.5, Driven by T-Cell Responses  ATLANTA, GA - June 9, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.

Data from Two Key Studies Highlight CrossReactivity and BroadSpectrum Immunity of GEO-CM04S1 and GeoVax Multi-Antigen Vaccine ...

MVA Technology: Protecting the Immunocompromised with Durable, Multi-Antigen Vaccines GeoVax's MVA platform supports a pipeline of multi-antigen vaccines, including GEO-CM04S1 (COVID-19 ...

Our GeoVax Labs Inc consensus estimates page is based on consensus analyst forecast, covering public companies earnings per share and revenue. You'll be provided with GeoVax Labs overall consensus ...

ATLANTA, GA - May 27, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced its ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon and welcome everyone to the GeoVax Third Quarter 2024 Corporate Update Call. My name is ...

John N. Spencer Jr., a director at GeoVax Labs, Inc. (NASDAQ:GOVX), recently purchased 10,000 shares of the company's common... GeoVax Labs, Inc. (NASDAQ:GOVX) President and CEO, David A. Dodd, has ...